{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:13:20Z","timestamp":1791965600962,"version":"4.3.4"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pharmthera.2026.109050","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:47:50Z","timestamp":1779205670000},"page":"109050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bioactive lipids in plasma and atherogenic apoB-containing lipoproteins: Effects of statins and PCSK9 inhibitors and relevance to residual cardiovascular risk"],"prefix":"10.1016","volume":"284","author":[{"given":"M. John","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Therond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Meikle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/17460875.2.2.229","article-title":"Triacylglycerol metabolism in adipose tissue","volume":"2","author":"Ahmadian","year":"2007","journal-title":"Future Lipidology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2005.05.006","article-title":"The effect of statin therapy on lipoprotein associated phospholipase A2 levels","volume":"182","author":"Albert","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014a new world-wide definition. A Consensus Statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0020","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.116.023233","article-title":"Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus","volume":"134","author":"Alshehry","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0025","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3390\/biomedicines9121941","article-title":"An untargeted lipidomic analysis reveals depletion of several phospholipid classes in patients with familial hypercholesterolemia on treatment with evolocumab","volume":"9","author":"Anesi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104445","article-title":"Exogenous GM3 ganglioside inhibits atherosclerosis via multiple steps: A potential atheroprotective drug","volume":"148","author":"Ao","year":"2019","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/metabo6010006","article-title":"Lysophosphatidylinositol signalling and metabolic diseases","volume":"6","author":"Arifin","year":"2016","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein (a) and cardiovascular and valvular diseases: A genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1152\/physrev.00028.2012","article-title":"Phosphoinositides: Tiny lipids with giant impact on cell regulation","volume":"93","author":"Balla","year":"2013","journal-title":"Physiological Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109050_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041456","article-title":"Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes","volume":"7","author":"Barber","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0060","doi-asserted-by":"crossref","first-page":"2230 2239","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0065","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/cdd.2016.11","article-title":"Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer","volume":"23","author":"Birge","year":"2016","journal-title":"Cell Death and Differentiation"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein (a) is markedly more atherogenic than LDL: An apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109050_bb0075","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0080","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1194\/jlr.M079012","article-title":"Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950\u2013 Metabolites in Frozen Human Plasma","volume":"58","author":"Bowden","year":"2017","journal-title":"Journal of Lipid Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0085","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1194\/jlr.S087163","article-title":"MS-based lipidomics of human blood plasma: A community-initiated position paper to develop accepted guidelines","volume":"59","author":"Burla","year":"2018","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.ircmb.2015.10.001","article-title":"Phosphatidylethanolamine metabolism in health and disease","volume":"321","author":"Calzada","year":"2016","journal-title":"International Review of Cell and Molecular Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0095","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","article-title":"Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids","volume":"33","author":"Camont","year":"2013","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s42004-019-0175-7","article-title":"Local accumulation of diacylglycerol alters membrane properties nonlinearly due to its transbilayer activity","volume":"2","author":"Campomanes","year":"2019","journal-title":"Communications Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2023.105348","article-title":"Lipidomic analysis identified potential predictive biomarkers of statin response in subjects with familial hypercholesterolemia","volume":"257","author":"Cerda","year":"2023","journal-title":"Chemistry and Physics of Lipids"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/01.ATV.0000069208.20268.D0","article-title":"Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor","volume":"23","author":"Chang","year":"2003","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0076-6879(86)28063-5","article-title":"Comparative analysis of mammalian plasma lipoproteins","volume":"128","author":"Chapman","year":"1986","journal-title":"Methods in Enzymology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0120","article-title":"Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of eicosapentaenoic acid","volume":"240","author":"Chapman","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100494","article-title":"Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia","volume":"65","author":"Chapman","year":"2024","journal-title":"Journal of Lipid Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0130","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacl.2018.02.001","article-title":"Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome","volume":"12","author":"Chapman","year":"2018","journal-title":"Journal of Clinical Lipidology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1194\/jlr.P119000543","article-title":"LDL subclass lipidomics in atherogenic dyslipidemia: Effect of statin therapy on bioactive lipids and dense LDL","volume":"61","author":"Chapman","year":"2020","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120529","article-title":"Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know","volume":"410","author":"Chapman","year":"2025","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2015.07.006","article-title":"Ceramides\u2014lipotoxic inducers of metabolic disorders","volume":"26","author":"Chaurasia","year":"2015","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fimmu.2018.00038","article-title":"Bioactive lipids and chronic inflammation: Managing the fire within","volume":"9","author":"Chiurchi\u00f9","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0155","first-page":"393","article-title":"Oxidized cholesteryl esters and inflammation. Biochimica et Biophysica Acta \u2013 Molecular and Cell Biology of","volume":"1862","author":"Choi","year":"2017","journal-title":"Lipids"},{"issue":"9976","key":"10.1016\/j.pharmthera.2026.109050_bb0160","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108812","article-title":"Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?","volume":"268","author":"Corsini","year":"2025","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.12997\/jla.2020.9.1.172","article-title":"Genetic architecture of circulating very-long-chain (C24:0 and C22:0) ceramide concentrations","volume":"9","author":"Cresci","year":"2020","journal-title":"Journal of Lipid and Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s43556-025-00321-3","article-title":"Cholesterol metabolism: Molecular mechanisms, biological functions, diseases, and therapeutic targets","volume":"6","author":"Cui","year":"2025","journal-title":"Molecular Biomedicine"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-94-007-3015-1_3","article-title":"Phosphoinositides in the mammalian endo-lysosomal network","volume":"59","author":"Cullen","year":"2012","journal-title":"Subcellular Biochemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0185","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jacl.2023.07.003","article-title":"Integrated omics approach for the identification of HDL structure\u2013function relationships in PCSK9- related familial hypercholesterolemia","volume":"17","author":"Darabi","year":"2023","journal-title":"Journal of Clinical Lipidology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2026.109050_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13646","article-title":"Residual cardiovascular risk among people with diabetes","volume":"21","author":"Dash","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/srep00139","article-title":"A phospholipidomic analysis of all defined human plasma lipoproteins","volume":"1","author":"Dashti","year":"2011","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109050_bb0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbalip.2009.01.002","article-title":"Niemann\u2013Pick C1-Like 1 (NPC1L1): An intestinal sterol transporter","volume":"1791","author":"Davis","year":"2009","journal-title":"Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0205","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13238-017-0423-5","article-title":"Structural and functional roles of ether lipids","volume":"9","author":"Dean","year":"2018","journal-title":"Protein & Cell"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid storm in infection and inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0215","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF01716251","article-title":"Regulation of cholesterol metabolism in man and in other species","volume":"62","author":"Dietschy","year":"1984","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0225","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/ATVBAHA.123.319937","article-title":"Diacylglycerols and lysophosphatidic acid enriched on lipoprotein(a) contribute to monocyte inflammation","volume":"44","author":"Dzobo","year":"2024","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0230","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.116.305675","article-title":"Sphingolipids contribute to human atherosclerotic plaque inflammation","volume":"36","author":"Edsfeldt","year":"2016","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1388-1981(00)00140-2","article-title":"Regulation of gene expression by SREBP and SCAP","volume":"1529","author":"Edwards","year":"2000","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.121.056805","article-title":"Deep lipidomics in human plasma: Cardiometabolic disease risk and effect of dietary fat modulation","volume":"146","author":"Eichelmann","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0245","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1007\/s00018-015-1982-3","article-title":"DAG tales: The multiple faces of diacylglycerol\u2014stereochemistry, metabolism, and signaling","volume":"72","author":"Eichmann","year":"2015","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0250","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"European Heart Journal"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109050_bb0255","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0260","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nature Reviews Cardiology"},{"issue":"32","key":"10.1016\/j.pharmthera.2026.109050_bb0265","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12154-016-0159-3","article-title":"Is phosphatidylglycerol essential for terrestrial life?","volume":"10","author":"Furse","year":"2016","journal-title":"Journal of Chemical Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294498","article-title":"Effect of statin treatment on metabolites, lipids and prostanoids in patients with statin associated muscle symptoms (SAMS)","volume":"18","author":"Garrett","year":"2023","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2026.109050_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2009.10.002","article-title":"Macrophage cholesteryl ester mobilization and atherosclerosis","volume":"52","author":"Ghosh","year":"2010","journal-title":"Vascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106345","article-title":"7\u03b2- Hydroxycholesterol and 7-ketocholesterol: New oxidative stress biomarkers of sarcopenia inducing cytotoxic effects on myoblasts and myotubes","volume":"232","author":"Ghzaiel","year":"2023","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0290","doi-asserted-by":"crossref","first-page":"1191303","DOI":"10.3389\/fcvm.2023.1191303","article-title":"Proteomics and lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: A narrative review","volume":"10","author":"Gianazza","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"47","key":"10.1016\/j.pharmthera.2026.109050_bb0295","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies","volume":"42","author":"Ginsberg","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0300","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","article-title":"Diabetic dyslipidemia: Causes and consequences","volume":"86","author":"Goldberg","year":"2001","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: From plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0310","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1042\/EBC20190091","article-title":"Role of bioactive sphingolipids in physiology and pathology","volume":"64","author":"Gomez-Larrauri","year":"2020","journal-title":"Essays in Biochemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0315","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.ATV.17.4.786","article-title":"Plasma LDL and HDL subspecies are heterogeneous in particle contents of tocopherols and oxygenated and hydrocarbon carotenoids","volume":"17","author":"Goulinet","year":"1997","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109050_bb0320","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11154-016-9402-z","article-title":"Dyslipidemia in patients with chronic kidney disease","volume":"18","author":"Hager","year":"2017","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0330","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1194\/jlr.M085233","article-title":"5,6-DiHETE attenuates vascular hyperpermeability by inhibiting Ca2+ elevation in endothelial cells","volume":"59","author":"Hamabata","year":"2018","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0335","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/180705","article-title":"Sphingosine-1-phosphate distribution in human plasma: Associations with lipid profiles","volume":"2012","author":"Hammad","year":"2012","journal-title":"Journal of Lipids"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100813","article-title":"The bioactive sphingolipid playbook: A primer for the uninitiated as well as sphingolipidologists","volume":"66","author":"Hannun","year":"2025","journal-title":"Journal of Lipid Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0345","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","article-title":"Hypertriglyceridemia- associated pancreatitis: New concepts and potential mechanisms","volume":"69","author":"Hansen","year":"2023","journal-title":"Clinical Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0350","first-page":"423","article-title":"Cholesteryl ester-rich inclusions from human aortic fatty streak and fibrous plaque lesions of atherosclerosis","volume":"75","author":"Hata","year":"1974","journal-title":"American Journal of Pathology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109050_bb0355","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0360","article-title":"The evolution of lipid-lowering drugs in the management of cardiovascular risk","volume":"77","author":"Henry","year":"2025","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","article-title":"PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions","volume":"269","author":"Hilvo","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0370","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jchromb.2015.03.010","article-title":"Lipidomic analysis of plasma, erythrocytes and lipoprotein fractions of cardiovascular disease patients using UHPLC\/MS, MALDI-MS and multivariate data analysis","volume":"990","author":"Hol\u010dapek","year":"2015","journal-title":"Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0380","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/s42255-023-00880-1","article-title":"Dynamic lipidome alterations associated with human health, disease and ageing","volume":"5","author":"Hornburg","year":"2023","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0385","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1161\/ATVBAHA.124.321058","article-title":"One- year effects of high-intensity statin on bioactive lipids: Findings from the JUPITER trial","volume":"44","author":"Hoshi","year":"2024","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0395","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/bies.950131108","article-title":"Biological activities of oxygenated sterols: Physiological and pathological implications","volume":"13","author":"Hwang","year":"1991","journal-title":"BioEssays"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109050_bb0400","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1111\/febs.16076","article-title":"Homeostatic and pathogenic roles of the GM3 ganglioside","volume":"289","author":"Inokuchi","year":"2022","journal-title":"The FEBS Journal"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109050_bb0405","first-page":"1475","article-title":"New insights on glucosylated lipids: Metabolism and functions. Biochimica et Biophysica Acta \u2013 Molecular and Cell Biology of","volume":"1831","author":"Ishibashi","year":"2013","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0410","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2013.03.029","article-title":"Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of PCSK9 deficiency","volume":"228","author":"J\u00e4nis","year":"2013","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109050_bb0415","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128438","article-title":"Changes in plasma lipids predict pravastatin efficacy in secondary prevention","volume":"4","author":"Jayawardana","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0420","first-page":"16148","article-title":"The role of sphingolipids in endothelial barrier function","volume":"290","author":"Jernigan","year":"2015","journal-title":"Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109050_bb0425","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/1873-3468.13465","article-title":"On the road to unraveling the molecular functions of ether lipids","volume":"593","author":"Jim\u00e9nez-Rojo","year":"2019","journal-title":"FEBS Letters"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109050_bb0430","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0435","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11306-010-0207-x","article-title":"Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study","volume":"6","author":"Kaddurah-Daouk","year":"2010","journal-title":"Metabolomics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clinical Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0445","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0022-2275(20)38106-2","article-title":"Cholesterol turnover in lipid phases of human atherosclerotic plaque","volume":"23","author":"Katz","year":"1982","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0450","doi-asserted-by":"crossref","first-page":"15973","DOI":"10.1038\/s41598-021-95455-z","article-title":"Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction","volume":"11","author":"Klassen","year":"2021","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109050_bb0455","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/cvr\/cvaf093","article-title":"Ceramides in cardiovascular disease: Emerging role as independent risk predictors and novel therapeutic targets","volume":"121","author":"Klingenberg","year":"2025","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0460","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/ijms21124501","article-title":"An updated review of pro- and anti-inflammatory properties of plasma lysophosphatidylcholines in the vascular system","volume":"21","author":"Knuplez","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109050_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100621","article-title":"The lipidomics reporting checklist: A framework for transparency of lipidomic experiments and repurposing resource data","volume":"65","author":"Kopczynski","year":"2024","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0475","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.athplu.2025.09.003","article-title":"Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated lipoprotein(a)","volume":"61","author":"Koutsogianni","year":"2025","journal-title":"Atherosclerosis Plus"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194797","article-title":"Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow","volume":"13","author":"Kuklenyik","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0485","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1194\/jlr.P071803","article-title":"Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome","volume":"58","author":"Kurano","year":"2017","journal-title":"Journal of Lipid Research"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109050_bb0490","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0495","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1152\/ajpendo.00330.2020","article-title":"Dihydroceramides: Their emerging physiological roles and functions in cancer and metabolic diseases","volume":"320","author":"Lachkar","year":"2021","journal-title":"American Journal of Physiology Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0500","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1038\/s41467-025-61911-x","article-title":"Computationally unmasking each fatty acyl C=C position in complex lipids by routine LC- MS\/MS lipidomics","volume":"16","author":"Lamp","year":"2025","journal-title":"Nature Communications"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109050_bb0505","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 update of ESC\/EAS task force on practical clinical guidance for PCSK9 inhibition","volume":"39","author":"Landmesser","year":"2018","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0510","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/ijms20051149","article-title":"An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases","volume":"20","author":"Law","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chemphyslip.2018.05.005","article-title":"Regulation of endogenic metabolites by rosuvastatin in hyperlipidemia patients: An integration of metabolomics and lipidomics","volume":"214","author":"Lee","year":"2018","journal-title":"Chemistry and Physics of Lipids"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0520","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCRESAHA.111.256859","article-title":"Role of phospholipid oxidation products in atherosclerosis","volume":"111","author":"Lee","year":"2012","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0525","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0530","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0540","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1194\/jlr.S120001025","article-title":"Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures","volume":"61","author":"Liebisch","year":"2020","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0545","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0550","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1007\/s00216-022-04351-6","article-title":"Simultaneous profiling and quantification of 25 eicosanoids in human serum by ultrahigh-performance liquid chromatography coupled to tandem mass spectrometry","volume":"414","author":"Lu","year":"2022","journal-title":"Analytical and Bioanalytical Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0555","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0560","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.jacl.2023.10.009","article-title":"Effect of PCSK9 inhibition on plasma levels of small dense low density lipoprotein-cholesterol and 7- ketocholesterol","volume":"18","author":"Mahmood","year":"2024","journal-title":"Journal of Clinical Lipidology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0565","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1194\/jlr.R046920","article-title":"Novel lysophosphoplipid receptors: their structure and function","volume":"55","author":"Makide","year":"2014","journal-title":"Journal of Lipid Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0570","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0891-5849(00)00234-3","article-title":"Bioactive phospholipid oxidation products","volume":"28","author":"Marathe","year":"2000","journal-title":"Free Radical Biology and Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100780","article-title":"Clinical lipidomics reveals high individuality and sex specificity of circulatory lipid signatures: a prospective healthy population study","volume":"66","author":"Medina","year":"2025","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0580","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.02.001","article-title":"Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease","volume":"143","author":"Meikle","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109050_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074341","article-title":"Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes","volume":"8","author":"Meikle","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0590","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1194\/jlr.P061143","article-title":"Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia","volume":"56","author":"Meikle","year":"2015","journal-title":"Journal of Lipid Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109050_bb0595","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1161\/ATVBAHA.111.234096","article-title":"Plasma lipidomic analysis of stable and unstable coronary artery disease","volume":"31","author":"Meikle","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0600","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1043-6618(03)00054-9","article-title":"Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action","volume":"47","author":"Menaldino","year":"2003","journal-title":"Pharmacological Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0605","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014402","article-title":"Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors","volume":"9","author":"Miao","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0610","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1742-1241.2005.00461.x","article-title":"Pitavastatin","volume":"59","author":"Mukhtar","year":"2005","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.pharmthera.2026.109050_bib1068","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121326","article-title":"Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention","volume":"3","author":"Mundra","year":"2018","journal-title":"JCI Insight"},{"issue":"10440","key":"10.1016\/j.pharmthera.2026.109050_bb0615","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Naghavi","year":"2024","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100492","article-title":"Wide-scope targeted analysis of bioactive lipids in human plasma by LC\/MS\/MS","volume":"65","author":"Nakatani","year":"2024","journal-title":"Journal of Lipid Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0625","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1210\/jc.2014-4348","article-title":"Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment","volume":"100","author":"Ng","year":"2015","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109050_bb0630","doi-asserted-by":"crossref","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","article-title":"Dose- dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome","volume":"99","author":"Ng","year":"2014","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0635","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiology"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109050_bb0640","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.3390\/ijms232012449","article-title":"Molecular characterization of plasma HDL, LDL, and VLDL lipids cargos from atherosclerotic patients with advanced carotid lesions: a preliminary report","volume":"23","author":"Nieddu","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"45","key":"10.1016\/j.pharmthera.2026.109050_bb0645","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"European Heart Journal"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109050_bb0650","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein (a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0655","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag087","article-title":"Residual lipid risk in atherosclerotic cardiovascular disease","author":"Nordestgaard","year":"2026","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109050_bb0660","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/eurheartj\/ehad161","article-title":"Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction","volume":"44","author":"Nurmohamed","year":"2023","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0665","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.plefa.2008.03.003","article-title":"Hypertriglyceridemia and hypercholesterolemia: effects of drug treatment on fatty acid composition of plasma lipids and membranes","volume":"78","author":"Nyalala","year":"2008","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"key":"10.1016\/j.pharmthera.2026.109050_bib1066","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/intimm\/dxz037","article-title":"Sphingosine 1-phosphate and inflammation","volume":"31","author":"Obinata","year":"2019","journal-title":"Int Immunol"},{"issue":"44","key":"10.1016\/j.pharmthera.2026.109050_bb0670","doi-asserted-by":"crossref","first-page":"29127","DOI":"10.1074\/jbc.273.44.29127","article-title":"Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low-density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans","volume":"273","author":"O\u00f6rni","year":"1998","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109050_bb0675","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1194\/jlr.P068585","article-title":"Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia","volume":"57","author":"Orsoni","year":"2016","journal-title":"Journal of Lipid Research"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109050_bb0680","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/heartjnl-2020-318760","article-title":"Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges","volume":"107","author":"Packard","year":"2021","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109050_bib1067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135228","article-title":"Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction","volume":"10","author":"Park","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100808","article-title":"Modulation of endogenous plasmalogens by genetic ablation of lysoplasmalogenase (Tmem86b) in mice","volume":"66","author":"Paul","year":"2025","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100092","article-title":"Shark liver oil supplementation enriches endogenous plasmalogens and reduces markers of dyslipidemia and inflammation","volume":"62","author":"Paul","year":"2021","journal-title":"Journal of Lipid Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0695","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007931","article-title":"Ceramide remodeling and risk of cardiovascular events and mortality","volume":"7","author":"Peterson","year":"2018","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0700","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbalip.2012.01.009","article-title":"Lysophosphatidylinositol signalling: new wine from an old bottle","volume":"1821","author":"Pi\u00f1eiro","year":"2012","journal-title":"Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0705","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0710","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1038\/s41467-023-43892-x","article-title":"Nonuniversal impact of cholesterol on membranes mobility, curvature sensing and elasticity","volume":"14","author":"P\u00f6hnl","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118569","article-title":"Phospholipid-derived lysophospholipids in (patho)physiology","volume":"398","author":"Prabutzki","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0720","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3389\/fphys.2018.01165","article-title":"Lipidomics reveals a tissue-specific fingerprint","volume":"9","author":"Pradas","year":"2018","journal-title":"Frontiers in Physiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109050_bb0725","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1194\/jlr.M009449","article-title":"Lipidomics reveals a remarkable diversity of lipids in human plasma","volume":"51","author":"Quehenberger","year":"2010","journal-title":"Journal of Lipid Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100647","article-title":"Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease","volume":"65","author":"Quehenberger","year":"2024","journal-title":"Journal of Lipid Research"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109050_bb0735","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMra1104901","article-title":"The human plasma lipidome","volume":"365","author":"Quehenberger","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109050_bb0740","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3390\/ijms22115793","article-title":"A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis","volume":"22","author":"Quinville","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155211","article-title":"Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation","volume":"132","author":"Radbakhsh","year":"2022","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0750","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/omi.2016.0178","article-title":"Novel Lipidomic Biomarkers in Hyperlipidemia and Cardiovascular Diseases: An Integrative Biology Analysis","volume":"21","author":"Rai","year":"2017","journal-title":"OMICS"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109050_bb0755","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012415","article-title":"Coronary artery disease risk and lipidomic profiles are similar in hyperlipidemias with family history and population-ascertained hyperlipidemias","volume":"8","author":"R\u00e4m\u00f6","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0760","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00015","article-title":"Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo","volume":"7","author":"Reddy","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109050_bb0765","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109050_bib1069","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England journal of medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0770","article-title":"Polygenic hyperlipidemias and coronary artery disease risk","volume":"13","author":"Ripatti","year":"2020","journal-title":"Circulation: Genomic and Precision Medicine"},{"issue":"2-3","key":"10.1016\/j.pharmthera.2026.109050_bb0775","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2007.06.021","article-title":"Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells","volume":"571","author":"Ris\u00e9","year":"2007","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0780","doi-asserted-by":"crossref","first-page":"1550500","DOI":"10.3389\/fimmu.2025.1550500","article-title":"Bioactive lipid signaling and lipidomics in macrophage polarization: Impact on inflammation and immune regulation","volume":"16","author":"Rodr\u00edguez","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.859421","article-title":"Plasmalogenic lipid analogs as platelet-activating factor antagonists: a potential novel class of anti-inflammatory compounds","volume":"10","author":"Rong","year":"2022","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0790","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1073\/pnas.81.18.5748","article-title":"Diacylglycerol stimulates DNA synthesis and cell division in mouse 3T3 cells: role of Ca2+-sensitive phospholipid-dependent protein kinase","volume":"81","author":"Rozengurt","year":"1984","journal-title":"Proceedings of the National Academy of Sciences U S A"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0795","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/CIRCULATIONAHA.111.063487","article-title":"Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes","volume":"125","author":"Ryu","year":"2012","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109050_bb0800","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0805","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bcp.12854","article-title":"Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials","volume":"81","author":"Sahebkar","year":"2016","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0810","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1172\/JCI107694","article-title":"Assay of total plasma apolipoprotein B concentration in human subjects","volume":"53","author":"Schonfeld","year":"1974","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/db12-0466","article-title":"Acylcarnitines: Reflecting or Inflicting Insulin Resistance?","volume":"62","author":"Schooneman","year":"2013","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0820","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000830","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction","volume":"33","author":"Schwartz","year":"2022","journal-title":"Current Opinion in Lipidology"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109050_bb0825","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109050_bb0830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11306-020-01709-8","article-title":"Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis","volume":"16","author":"Seah","year":"2020","journal-title":"Metabolomics"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109050_bb0835","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0840","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.chemphyslip.2015.05.005","article-title":"Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry","volume":"189","author":"Serna","year":"2015","journal-title":"Chemistry and Physics of Lipids"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0845","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.816301","article-title":"Role of ceramides in the molecular pathogenesis and potential therapeutic strategies of cardiometabolic diseases: what we know so far","volume":"9","author":"Shalaby","year":"2022","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0850","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.0000080895.05158.8B","article-title":"Statins promote potent systemic antioxidant effects through specific inflammatory pathways","volume":"108","author":"Shishehbor","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb0855","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1042\/bj1040340","article-title":"Lipid composition of human serum lipoproteins","volume":"104","author":"Skipski","year":"1967","journal-title":"Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0860","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12944-021-01456-2","article-title":"Age and sex are associated with the plasma lipidome: findings from the GOLDN study","volume":"20","author":"Slade","year":"2021","journal-title":"Lipids in Health and Disease"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2026.109050_bb0865","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0009-3084(99)00071-7","article-title":"Sphingomyelin-cholesterol interactions in biological and model membranes","volume":"102","author":"Slotte","year":"1999","journal-title":"Chemistry and Physics of Lipids"},{"issue":"4147","key":"10.1016\/j.pharmthera.2026.109050_bb0870","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1126\/science.185.4147.222","article-title":"Physical-chemical basis of lipid deposition in atherosclerosis","volume":"185","author":"Small","year":"1974","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0875","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109050_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2024.100252","article-title":"Ceramides as emerging players in cardiovascular disease: focus on their pathogenetic effects and regulation by diet","volume":"15","author":"Spaggiari","year":"2024","journal-title":"Advances in Nutrition"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0885","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00125-011-2444-6","article-title":"Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes","volume":"55","author":"St\u00e5hlman","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108420","article-title":"Bioactive lipid regulation of platelet function, hemostasis, and thrombosis","volume":"246","author":"Stanger","year":"2023","journal-title":"Pharmacology & Therapeutics"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109050_bb0895","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1161\/CIRCULATIONAHA.113.002500","article-title":"Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study","volume":"129","author":"Stegemann","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0900","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"The American Journal of Cardiology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167806","article-title":"Lipidomics and cardiovascular disease","volume":"1871","author":"Surendran","year":"2025","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101068","article-title":"Emerging roles of lysophospholipids in health and disease","volume":"80","author":"Tan","year":"2020","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0915","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1038\/s41598-019-46461-9","article-title":"Fatty acid desaturase 2 is up-regulated by the treatment with statin through geranylgeranyl pyrophosphate-dependent Rho kinase pathway in HepG2 cells","volume":"9","author":"Tanaka","year":"2019","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109050_bb0920","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1210\/jc.2013-2559","article-title":"Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency","volume":"99","author":"Tarasov","year":"2014","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0925","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MOL.0000000000000825","article-title":"Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment","volume":"33","author":"Therond","year":"2022","journal-title":"Current Opinion in Lipidology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109050_bb0930","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology: cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"European Heart Journal"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109050_bb0935","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0940","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOL.0b013e328308b622","article-title":"The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity","volume":"19","author":"Tsimikas","year":"2008","journal-title":"Current Opinion in Lipidology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb0945","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114739119","article-title":"Triglyceride breakdown from lipid droplets regulates the inflammatory response in macrophages","volume":"119","author":"Van Dierendonck","year":"2022","journal-title":"Proceedings of the National Academy of Sciences U S A."},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0950","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbalip.2012.08.016","article-title":"Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells","volume":"1831","author":"Vance","year":"2013","journal-title":"Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109050_bb0955","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease","volume":"1859","author":"van der Veen","year":"2017","journal-title":"Biochimica et Biophysica Acta, Biomembranes"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb0960","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1096\/fj.201802117R","article-title":"A role for phosphatidylcholine and phosphatidylethanolamine in hepatic insulin signaling","volume":"33","author":"van der Veen","year":"2019","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2026.109050_bb0965","first-page":"1","article-title":"Plaque rupture and plaque erosion","volume":"82","author":"Virmani","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109050_bb0970","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"34","key":"10.1016\/j.pharmthera.2026.109050_bb0975","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0980","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.chemphyslip.2011.06.008","article-title":"Plasmalogens the neglected regulatory and scavenging lipid species","volume":"164","author":"Wallner","year":"2011","journal-title":"Chemistry and Physics of Lipids"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0985","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.008552","article-title":"Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis","volume":"15","author":"Wang","year":"2022","journal-title":"Circulation. Cardiovascular Quality and Outcomes"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109050_bb0990","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/cells9061391","article-title":"Bioactive lipid signaling in cardiovascular disease, development, and regeneration","volume":"9","author":"Wasserman","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.11.015","article-title":"Directed non-targeted mass spectrometry and chemical networking for discovery of eicosanoids and related oxylipins","volume":"26","author":"Watrous","year":"2019","journal-title":"Cell Chemical Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109050_bb1000","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1194\/jlr.P035808","article-title":"Plasma lipid profiling in a large population-based cohort","volume":"54","author":"Weir","year":"2013","journal-title":"Journal of Lipid Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb1005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109050_bb1015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"Wiesner","year":"2009","journal-title":"Journal of Lipid Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109050_bb1020","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/ATVBAHA.124.319983","article-title":"Immune-mediated inflammatory diseases, dyslipidemia, and cardiovascular risk: A complex interplay","volume":"44","author":"Wilkinson","year":"2024","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb1025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2024.04.060","article-title":"Lipidomic risk score to enhance cardiovascular risk stratification for primary prevention","volume":"84","author":"Wu","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109050_bb1030","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1074\/jbc.R117.000582","article-title":"Phospholipid subcellular localization and dynamics","volume":"293","author":"Yang","year":"2018","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109050_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100800","article-title":"Statin effects on the lipidome: predicting statin usage and implications for cardiovascular risk prediction","volume":"66","author":"Yi","year":"2025","journal-title":"Journal of Lipid Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109050_bb1040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/cvr\/cvab032","article-title":"Emerging views of statin pleiotropy and cholesterol lowering","volume":"118","author":"Yu","year":"2022","journal-title":"Cardiovascular Research"},{"issue":"9438","key":"10.1016\/j.pharmthera.2026.109050_bb1045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2026.109050_bb1050","doi-asserted-by":"crossref","first-page":"1726925","DOI":"10.3389\/fphar.2025.1726925","article-title":"Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease","volume":"16","author":"Zhang","year":"2025","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109050_bb1060","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/gix036","article-title":"Lipidomic profiling reveals distinct differences in plasma lipid composition in healthy, prediabetic, and type 2 diabetic individuals","volume":"6","author":"Zhong","year":"2017","journal-title":"Gigascience"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109050_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26326","article-title":"Lipidomics based on UHPLC\/Q-TOF-MS to characterize lipid metabolic profiling in patients with newly diagnosed type 2 diabetes mellitus with dyslipidemia","volume":"10","author":"Zhong","year":"2024","journal-title":"Heliyon"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582600077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582600077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:16:34Z","timestamp":1781097394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582600077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":212,"alternative-id":["S016372582600077X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109050","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioactive lipids in plasma and atherogenic apoB-containing lipoproteins: Effects of statins and PCSK9 inhibitors and relevance to residual cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109050"}}